Global health authorities, including those in the United States, are now discontinuing support for animal model-based research and transitioning towards adopting new assessment systems (NAMs). This trend is rapidly elevating the importance of alternative platforms such as organoids, organ-on-a-chip technologies, and AI-based in silico models. These alternatives, capable of enhancing R&D efficiency and predictive accuracy, are being recognized as a critical turning point, presenting significant opportunities for related companies. For biotech ventures like HADD Science, this is a decisive moment to secure technological leadership. As human-centric, data-driven evaluation establishes itself as the new standard, existing animal-based non-clinical systems are quickly becoming relics of a bygone era. The time has come for a 'transition,' not merely a 'choice.'